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Abstract
Delays in rotavirus vaccine schedule could improve performance in low- and middle-income 
countries (LMICs). However, delaying the first dose could be detrimental if infants experience 
severe rotavirus gastroenteritis (RVGE) early in life. Our objective was to describe the timing 
and predictors of severe RVGE in unvaccinated children in LMICs. We analysed the placebo 
arms from two clinical trials (cohort 1: NCT00241644; cohort 2: NCT00362648). We esti-
mated the rate, cumulative incidence (per 1000 infants) and age distribution of severe 
RVGE episodes. Cox proportional hazards models were used to estimate hazard ratios and 
95% confidence intervals (CI) for the association between baseline factors and severe 
RVGE. Cumulative incidence at 6 months of age was 23/1000 (95% CI 15–30) in cohort 1 
and 6/1000 (95% CI 3–8) in cohort 2. Early antibiotic use (compared with no use) was asso-
ciated with 2.03 (95% CI 1.18–3.48) and 1.41 (95% CI 0.80–2.51) times the rate of severe 
RVGE in cohorts 1 and 2, respectively. The cumulative incidence of severe RVGE was low 
at 6 months of age, suggesting that a 4-week delay in the vaccination schedule may not result 
in a large number of severe RVGE episodes prior to vaccine receipt.
Introduction
Prior to global roll-out of rotavirus vaccines, rotavirus was the leading cause of severe diar-
rhoea in infants and children [1, 2]. Global surveillance estimates from 2009, before
widespread vaccination, indicated the median prevalence of rotavirus among children
hospitalised for gastroenteritis was 36% (range among countries: 12–68%) [3]. In the pre-
vaccine era, almost every child in the world was thought to experience rotavirus infection
[4, 5] and about one in every 260 children would die as a result of the infection [2].
Although the incidence of rotavirus gastroenteritis (RVGE) is similar in high-, middle- and
low-income countries, 80–90% of rotavirus-associated deaths occur in the world’s poorest
countries [1].
As of 2009, the World Health Organization recommended rotavirus vaccination for all
infants [6]. There are two live, oral rotavirus vaccines used broadly across the globe: a mono-
valent (Rotarix™, GlaxoSmithKline Biologicals, Rixensart, Belgium) and pentavalent vaccine
(RotaTeq™, Merck & Co., Inc.; Kenilworth, NJ, USA). While high protective 1-year efficacy
(96–98%) against severe RVGE has been reported in high-income countries (HICs) [7–9],
the efficacy has been much lower (51–64%) in trials conducted in low- and middle-income
countries (LMICs) [10–12].
One potential intervention that may increase the effectiveness of rotavirus vaccines in
LMICs is altering the vaccine schedule (number and/or timing) of rotavirus vaccines doses.
Recent research suggests delaying the start of the rotavirus vaccine series may result in
some gains in vaccine efficacy [10, 13–15], possibly due to less interference from transplacental
antibodies [13, 16]. However, first RVGE episode is thought to occur early in children in
LMICs (median 6–9 months) [17]. Consequently, delaying vaccination could result in severe
RVGE occurring prior to administration of the vaccine.
Therefore, it is important to understand the timing of severe RVGE among unvaccinated
children to be able to weigh the potential advantages and disadvantages of delaying vaccin-
ation schedules. Although there have been a number of studies investigating the natural history
of rotavirus [18–23], these studies have not provided data on the cumulative incidence of
severe RVGE over the first few years of life. In this study, we analysed the placebo arms of
two large rotavirus vaccine trials conducted in LMICs to better understand the timing and pre-
dictors of first severe RVGE episodes among unvaccinated children in LMICs.
We classified relevant nutrition indicators by using underweight,
stunted and wasting criteria specified by the World Health
Organization (WHO) [27]. Infant body length was not recorded
in Bangladesh; therefore, stunted and wasting status were not
determined for Bangladeshi infants. We also classified prior or
current antibiotic use using data collected in medical histories
taken at baseline (e.g. enrolment). Topical antibiotics were not
included in prior or current antibiotic use. Routine vaccines
were also classified to determine the number of doses received
prior to or at enrolment for all vaccines except Bacillus
Calmette–Guérin vaccine (BCG), which was classified based on
the receipt before enrolment. Severe RVGE was defined as a
Vesikari or modified-Vesikari score of >11. We also determined
the age at first severe RVGE episode. For cohort 1, the age of
enrolment was provided in weeks; therefore, the age of severe
RVGE may not be exact, but within 6 days of the actual age at
which the episode occurred.
To describe the timing of first severe RVGE episodes among
children in LMICs, we estimated the incidence rates and cumula-
tive incidence of first episodes of severe RVGE for each country as
well as the age distributions of first severe RVGE episodes by
cohort. Specifically, rates and exact 95% confidence intervals
[28] were estimated as the number of first severe RVGE episodes
from enrolment through one to 2 years of follow-up divided by
the person-time accumulated. To estimate the cumulative inci-
dence and 95% confidence interval of first severe RVGE episodes,
we obtained the complement of the extended Kaplan–Meier sur-
vival curve overall and stratified by country. Use of the extended
Kaplan–Meier survival curve allowed for late entry on an age-
specific time scale [29]. Follow-up began at 6 weeks of age and
continued until the first episode of severe RVGE occurred or
the infant was censored. Any infant who was recruited into either
study before 6 weeks of age began accumulating person-time at 6
weeks of age. Follow-up time in cohort 1 is within 6 days of the
exact number of days followed from 6 weeks of age because age
at enrolment was provided in weeks and follow-up was provided
as days from enrolment. Finally, among those experiencing a
severe RVGE episode, we described the median and interquartile
range (IQR) of the age of onset of first severe RVGE episodes by
cohort.
We were interested in what baseline patient characteristics
affected the rate of severe RVGE using the data that were available
in each cohort. To be evaluated as a potential predictor of first
severe RVGE episodes, we required at least ten severe RVGE epi-
sodes within each stratum of each factor. Baseline factors consid-
ered in both cohorts were sex (female/male), underweight status
(yes/no), prior or current infection (yes/no) at enrolment, prior
or current antibiotic use (yes/no) at enrolment, and receipt of
other vaccines. Other vaccines included were BCG receipt prior
to enrolment (0 vs. at least one); diphtheria–tetanus–pertussis–
Hepatitis B and –Haemophilus influenza B vaccine (DTP–HB/
HIB) or diphtheria and tetanus toxoids and acellular pertussis
vaccine (DTaP) and Hepatitis B vaccine (HB) receipt prior or at
enrolment (0 vs. at least one); and oral poliovirus vaccine
(OPV) receipt prior or at enrolment (one or fewer doses vs.
two). Stunted (yes/no) and wasting (yes/no) were considered as
potential predictors in only cohort 1 while exclusive breastfeeding
(yes/no) was considered as a potential predictor in only cohort 2.
We estimated the association between the baseline factors
described above and rates of first severe RVGE episodes using a
Cox proportional hazards model with the exact method to analyse
tied episodes. We assessed the proportional hazards assumption
Methods
Parent study data
This was an analysis of Phase III, placebo-controlled, multicentre 
randomised trials of monovalent (RV1) and pentavalent (RV5) rota-
virus vaccines in LMICs [Clinical Trial Numbers: NCT00241644 
(RV1) and NCT00362648 (RV5)]. Each trial has been described 
previously [10, 11, 24]. A brief overview of each trial follows.
In the RV1 trial, healthy infants, 5–10 weeks of age, were ran-
domly assigned to receive doses of vaccine or placebo at approxi-
mately 6, 10 and 14 weeks of age and were followed for 1–2 years 
of age. Beginning at enrolment, there was active surveillance of 
any gastroenteritis through weekly visits to parents or guardians 
to collect diary cards and through visits to health clinics that served 
the populations. Gastroenteritis was defined as three or more stools 
that were looser than normal within a 24 h period. Stool samples 
were collected during any episode of gastroenteritis and were ana-
lysed for the presence of rotavirus antigens using enzyme-linked 
immunosorbent assays (ELISA) (Rotaclone, Meridian Bioscience) 
with reverse transcription polymerase chain reaction (RT–PCR) 
confirmation. Severity was defined using the 20-point Vesikari clin-
ical score for PCR-confirmed RVGE episodes [25].
In the RV5 trial, enrolled infants, 4–12 weeks of age, were ran-
domly assigned to receive either three doses of pentavalent rota-
virus vaccine or placebo at approximately 6, 10 and 14 weeks of 
age and were followed for approximately 2 years. There was active 
surveillance at local clinics and hospitals for any occurrence of 
gastroenteritis occurring after study entry. Gastroenteritis was 
defined as three or more stools that were watery or looser than 
normal within a 24-h period, or forceful vomiting. Stool samples 
and patient histories were collected from infants presenting with 
symptoms of gastroenteritis. Stool samples were analysed for 
the presence of rotavirus antigens using an enzyme immunoassay 
with RT–PCR confirmation. The severity of disease was deter-
mined using the 20-point modified Vesikari clinical score for 
infants with PCR confirmed RVGE [12, 25, 26].
Study data
In this analysis, the objective was to describe the timing and pre-
dictors of first severe RVGE episodes among those not receiving 
the rotavirus vaccine; therefore, only the placebo arms of each 
trial were analysed. There were 1641 and 3753 infants randomised 
to receive only the placebo treatment in the RV1 trial (cohort 1) 
and the RV5 trial (cohort 2), respectively. In cohort 1, 27 (1.6%) 
infants were excluded because they were not randomised, their 
randomisation code was broken at the investigator site, the 
study vaccine dose was not administered according to the proto-
col, or they did not have at least one day of follow-up. In cohort 2, 
one infant (0.02%) was excluded because he or she received at 
least one dose of placebo. Each cohort was analysed separately, 
but the results are presented in parallel. This research was 
approved by the University of North Carolina at Chapel Hill 
Institutional Review Board.
Statistical analysis
Prior to analysis, we categorised all available data for variables 
measured at enrolment including demographic information, 
breastfeeding and growth status, prior or current infection, prior 
or current antibiotic use, routine vaccinations and severe RVGE. 
Breastfeeding status was classified as exclusive vs. non-exclusive.
by inspecting the plot of log(time) and log[−log(Survival)] for
each variable. Similar to the methods described above for estimat-
ing the incidence rates, follow-up began at 6 weeks of age for both
cohorts with late entry adjustment for those enrolled later. If more
than 10% of participants in either cohort discontinued follow-up,
we examined the potential for differential dropout (right censor-
ing) within each level of each predictor to determine if censoring
could be informative.
Crude and adjusted hazard ratios (HR) and 95% confidence
intervals were estimated and were considered statistically signifi-
cant at a cut-off of α = 0.05. Due to the low number of severe
RVGE episodes, we analysed each cohort separately, adjusted
for the country in the multivariable model, rather than fit individ-
ual models for each country. As a sensitivity analysis, we esti-
mated the crude and adjusted HRs for cohort 2 excluding Mali
and Kenya, because there were problems with gastroenteritis
surveillance in those countries [30].
All analyses were performed using SAS Clinical Trial Data
Transparency (Version 4.5.2; SAS Institute Inc., Cary, NC, USA).
Results
There were 1614 and 3752 children included in the analysis from
cohort 1 and two, respectively (Table 1). The median lengths of
follow-up to censoring or first severe RVGE episode were 327
and 518 days for cohorts 1 and 2, respectively (Table 2). The
majority of infants in both cohorts were African and enrolled at
6–7 weeks of age. In cohort 1, about 20% of children were stunted
and about 5% were underweight and 5% had wasting. In cohort 2,
about 10% were stunted, 10% were underweight and about 20%
had wasting. Prior or current infection at enrolment was reported
for about 5% and 20% of infants in cohorts 1 and 2, respectively.
Prior or current antibiotic use at enrolment was reported for
about 10% and 5% of cohorts 1 and 2, respectively.
There were 101 and 205 first episodes of severe RVGE in
cohorts 1 and 2, respectively (Table 2). The overall incidence
rates of first severe RVGE episodes were 5.6 (95% CI 4.6–6.9)
and 4.2 (95% CI 3.6–4.8) per 100 child-years in cohorts 1 and
2, respectively. The cumulative incidence and 95% confidence
interval (CI) of first severe RVGE episodes at different ages are
presented in Table 3. The median and IQR of the age of onset
for first severe RVGE episodes was 33.3 weeks (IQR: 23.6, 47.3)
in cohort 1 and 52.9 weeks (IQR: 34.1, 69.1) in cohort 2. There
was variability in the cumulative incidence by country (Fig. 1).
Prior or current antibiotic use at enrolment was associated a
twofold increase in the rate of first episodes of severe RVGE
[adjusted HR: 2.03 (95% CI 1.18–3.48)] compared with those
with no use in cohort 1 (Table 4). In cohort 2, the direction of
the association was similar with the rate of first severe RVGE epi-
sodes estimated at about one and half times the rate in those with
prior or current antibiotic use [adjusted HR: 1.41 (95% CI 0.80–
2.51)] compared with those with no use. In addition, in cohort 1,
females had a higher rate of severe RVGE compared with males
[adjusted HR: 1.43 (95% CI 0.96–2.12)]. No variables in cohort
2 were strongly associated with first episodes of severe RVGE,
but there was a lower rate of first severe RVGE episodes among
those who did not receive BCG before enrolment compared
with those who received one or more doses of BCG [adjusted
HR: 0.65 (95% CI 0.35–1.21)]. Results including and excluding
Kenya and Mali in the analysis were similar (Supplementary
Table S1).
In cohort 1, 17% of the study population dropped out or were
lost to follow-up prior to the end of the study. In cohort 2, 3.9% of
participants discontinued follow-up. Additional information on
loss to follow-up in cohort 1 can be found in Supplementary
Table S2.
Discussion
We analysed data from the placebo arms of two large trials con-
ducted in LMICs to describe the timing and predictors of first
severe RVGE episodes. The cumulative incidence of first severe
RVGE episodes was low at 6 months of age. Early antibiotic use
was associated with an increase in the rate of first severe RVGE
episodes in both cohorts.
The cumulative incidence of first severe RVGE episode
increased slowly but steadily over the first 1–2 years of life with
a low risk of rotavirus at 6 months of age. In cohort 1, almost
all severe RVGE cases occurred in the first year of life. This
could be due to fewer cases occurring in the second year of life
or because of decreased surveillance of gastroenteritis in that per-
iod. By contrast, severe RVGE events occurred steadily over about
the first 24 months of age in cohort 2. The differences in the ori-
ginal clinical trials may account for these and any other
Table 1. Characteristics of the placebo arms (cohorts 1 and 2) at enrolment
Baseline characteristic
Cohort 1
N = 1614
Cohort 2
N = 3752
Demographic
Age (weeks), median (IQR) 6 (6, 7) 7 (6, 9)
Female sex( %) 48.5 49.6
African race (%) 97.0 72.8
Asian race (%) 0.0 27.1
Exclusively breastfed (%) – 81.3
Growth status
Stunted (%) 22.1* 10.6†
Underweight (%) 4.5 11.1
Wasting (%) 4.2* 20.7*†
Prior/current infection (%) 4.2 19.4
Prior/current antibiotic‡ use (%) 9.2 5.6
Routine vaccines
⩾1 BCG§ (%) 95.2 74.0
⩾1 DTP–HB/HIB or DTaP & HB (%) 99.8 68.6
OPV
0 Dose (%) 0.0 8.3
1 Dose (%) 11.8 47.9
2 Doses (%) 87.6 37.6
⩾3 Doses (%) 0.6 6.2
IQR, interquartile range; BCG, Bacillus Calmette–Guérin vaccine; DTP–HB/HIB, diphtheria–
tetanus–pertussis–Hepatitis B and –Haemophilus influenza B vaccines; DTaP, diphtheria
and tetanus toxoids and acellular pertussis vaccine; HB, Hepatitis B vaccine; OPV, oral polio
vaccine; GMC, geometric mean concentration.
*Missing one to 15 observations.
†Excluding Bangladesh.
‡Excluding topical antibiotics.
§Administered prior to enrolment.
differences observed. For example, gastroenteritis and severity had
slightly different definitions in each trial, and there were different
mechanisms for capturing episodes of gastroenteritis (households
vs. health facilities). In addition, the study sites and inclusion cri-
teria were different for the two trials. Any of these factors may be
a partial or complete cause of any differences observed between
the two cohorts.
Although some studies have described age-specific rates of
RVGE or the distribution of age of RVGE onset [18, 19, 21, 31],
these studies have not differentiated episodes of severe and non-
severe RVGE or first vs. subsequent episodes of RVGE.
Therefore, due to different methods of presenting data, it is difficult
to compare the cumulative incidence estimates to those from prior
studies. However, in this study, we found did find the overall rates
of severe RVGE in cohorts 1 and 2 were similar or slightly higher
than previously reported estimates. A study in India reported the
incidence of severe RVGE in the first year of life to be five events
per 100 child-years [32], while another study in Pakistan reported
approximately two events per 100 child-years [33].
Given the low risk of severe RVGE at 6 months of age, a delay
of 4 weeks in the start of rotavirus vaccination could result in
fewer episodes of severe RVGE if delaying vaccination improved
Table 2. Rates of first severe RVGE by cohort and country
Cohort/country N Median days of follow-up*
First severe RVGE
Episodes Child-years Rate† (95% CI)
Cohort 1 1614 327 101 1790 5.6 (4.6–6.9)
Malawi 581 553 62 705 8.8 (6.7–11.3)
South Africa 1033 323 39 1084 3.6 (2.6–4.9)
Cohort 2 3752 518 205 4876 4.2 (3.6–4.8)
Ghana 1102 527 57 1431 4.0 (3.0–5.2)
Kenya 651 483 15 700 2.1 (1.2–3.5)
Mali 981 539 61 1331 4.6 (3.5–5.9)
Bangladesh 568 540 56 831 6.7 (5.1–8.8)
Vietnam 450 480 16 583 2.7 (1.6–4.5)
RVGE, rotavirus gastroenteritis.
*From enrolment.
†Per 100 Child-years.
Table 3. Cumulative incidence of first severe RVGE episodes at different ages in
cohorts 1 and 2
Cumulative incidence (95% CI) per 1000
infants
Cohort 1 Cohort 2
Age (months)
3 0.6 (0–2) 0
6 23 (15–30) 6 (3–8)
9 44 (34–55) 20 (16–25)
12 56 (44–68) 29 (24–35)
20 79 (63–95) 63 (54–72)
Fig. 1. Cumulative incidence of severe rotavirus gastroenteritis from 6 weeks of age in
cohort 1 (a) and cohort 2 (b). Number at risk at the start of follow-up and at 6 months
intervals is labelled at corresponding time points for each country below the x-axis.
the performance of the vaccine. Approximately 0.6–2.3% of
unvaccinated infants experienced severe RVGE by 6 months of
age. Therefore, the decision to delay the start of vaccination
would depend on the level of improvement in vaccine effective-
ness expected to occur with delayed vaccination, taking into
account a potential small increase in risk before 6 months of
age. Assessing timing of vaccination, the proportion of infants
who would be successfully vaccinated under the proposed sched-
ule and incidence of severe RVGE would be needed to understand
the potential benefits and harms of delaying vaccinations.
In both cohorts, we found that antibiotic use early in life was
associated with earlier first episodes of severe RVGE. To our
knowledge, antibiotic use has not been reported to be associated
with severe RVGE but has been linked to increased risk of diar-
rhoeal disease. Recent studies conducted in India found an
increased risk of diarrhoeal disease in children receiving antibio-
tics at less than 6 months of age compared with those who did not
[34], and a shorter time to the subsequent diarrhoeal episode
when the first episode was treated with antibiotics [35].
Antibiotics reduce the diversity of the gut microbiota and can
affect the early development of the infant microbiota [36]. It is
likely that microbial colonisation and diversification play a critical
role in susceptibility to diarrhoeal diseases and possibly severe
RVGE. Conversely, it is also possible that antibiotic use is an indi-
cation of children who are sicker and exposed to more pathogens
and are therefore more likely to develop severe RVGE. We were
unable to assess antibiotic use after enrolment, nor the indication,
duration and type of antibiotics received at enrolment. Further
analyses addressing these aspects would be helpful to understand
these results. Although antibiotic use being associated with severe
RVGE may have biological implications, this finding will not
likely have broad public health significance in administration in
the post-rotavirus vaccine era.
There are some limitations to this research. These data were
collected as part of clinical trials. Therefore, the participants
may not be generalisable to the broader study population of
infants in each country, because trials typically have strict inclu-
sion and exclusion criteria that do not always represent all the
children who will be routinely vaccinated. However, it should be
noted that there were few exclusion criteria for the RV5 trial,
and it seems plausible that the study population would be rela-
tively representative of all infants being vaccinated. In addition,
the study inclusion and exclusion criteria for both cohorts 1
and 2 did not specifically prohibit children who received the pla-
cebo from being in the same household or neighbourhood as chil-
dren who were vaccinated. If vaccinated children were nearby,
there may have been potential for herd protection, which would
decrease the number of unvaccinated (placebo) children with
RVGE. As a result, the incidence of first episodes of severe
RVGE in this study would not represent a completely unvaccin-
ated cohort. Also, we were unable to estimate the rates and cumu-
lative incidence of first severe RVGE episodes from birth, because
the trial recruited children around 6 weeks of age. This means we
have likely underestimated the incidence of first episodes of severe
RVGE in early childhood by missing severe RVGE episodes
occurring between birth and 6 weeks of age. Similarly, due to stag-
gered enrolment by age, the earliest time period we had sufficient
sample size to analyse the study populations was at 6 weeks of age.
Table 4. Predictors of first severe RVGE episodes in cohorts 1 and 2
Characteristic
Cohort 1*
N = 1613, Episodes = 100
Cohort 2*
N = 3746, Episodes = 205
Unadjusted†
HR (95% CI)
Adjusted†
HR (95% CI)
Unadjusted†
HR (95% CI)
Adjusted†
HR (95% CI)
Demographic
Female sex vs. male (ref) 1.44 (0.97–2.15) 1.43 (0.96–2.12) 0.86 (0.65–1.13) 0.86 (0.65–1.13)
Exclusively breastfed vs. not (ref) – – 0.75 (0.48–1.15) 0.75 (0.48–1.16)
Growth status
Stunted vs. not (ref) 0.78 (0.49–1.26) 0.75 (0.46–1.21) – –
Underweight vs. not (ref) ‡ ‡ 0.82 (0.52–1.30) 0.81 (0.51–1.29)
Wasting vs. not (ref) ‡ ‡ −- −-
Prior/current infection vs. none (ref) ‡ ‡ 0.99 (0.64–1.52) 0.89 (0.56–1.40)
Prior/current antibiotic§ Use vs. none (ref) 1.97 (1.15–3.36) 2.03 (1.18–3.48) 1.40 (0.81–2.41) 1.41 (0.80–2.51)
Routine vaccines
BCG‖; no dose vs. ⩾1 dose (ref) ‡ ‡ 0.63 (0.34–1.17) 0.65 (0.35–1.21)
DTP–HB/HIB¶; no dose vs. ⩾1 dose (ref) ‡ ‡ 1.00 (0.71–1.42) 1.08 (0.71–1.66)
OPV; ⩽1 dose vs. ⩾2 doses (ref) 0.79 (0.45–1.42) 0.80 (0.45–1.43) 0.94 (0.70–1.25) 0.95 (0.66–1.36)
BCG, Bacillus Calmette–Guérin vaccine; DTP–HB/HIB, diphtheria–tetanus–pertussis–Hepatitis B and –Haemophilus influenza B vaccines; DTaP, diphtheria and tetanus toxoids and acellular
pertussis vaccine; HB, Hepatitis B vaccine; OPV, oral polio vaccine.
*One infant in cohort 1 experienced an episode prior to 6 weeks of age and 6 infants from cohort 2 entered and exited the study before 6 weeks of age.
†Adjusted for country.
‡Less than ten episodes in each strata.
§Administered prior to enrolment.
‖Excluding topical antibiotics.
¶Or DTaP & HB, which were the standard vaccines given in Asian countries.
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This resulted in the exclusion of one severe RVGE episode from 
the cumulative incidence estimates and predictor analysis because 
the episode occurred prior to 6 weeks of age in cohort 1. Early 
episodes would be essential to include when weighing the option 
of beginning vaccination prior to 6 weeks of age. However, most 
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